Sensex extends gains, Nifty eyes 9900; all sectoral indices in green

Cadila HealthcareCadila Healthcare

Cadila Healthcare shares rallied 3 percent intraday after the launch of drug that used for the treatment of mild to moderate ulcerative colitis, in the US and the FDA approval for cholesterol drug.

Subsidiary Zydus Cadila has commercially launched its Mesalamine delayed release tablets (USP 1.2g) in the US market.

Zydus was the first to file an abbreviated new drug application (ANDA) for a generic version of Lialda and is currently the only generic available to patients in the US, the company said in its filing.

 The group has received 26 final ANDA approval from the US Food & Drug Administration and 2 tentative ANDA approvals since January 2017.

Meanwhile, Zydus Pharma, the US division of Cadila Healthcare, has received approval from USFDA for Pitavastatin that helps in lowering bad cholesterol & raising good cholesterol.

For more information ✆ – 0731-6642300 or Visit http://www.epicresearch.co

Facebook Twitter YouTube Pinterest Linkedin Google+

You may also like:

Sensex turns sluggish, Nifty still holds 9300; ICICI falls ahead of Q4' width= Sensex consolidates ahead of FOMC meet outcome; RBL Bank most active' width=
Sensex turns sluggish, Nifty still holds 9300; ICICI falls ahead of Q4 Sensex consolidates ahead of FOMC meet outcome; RBL Bank most active
Share Button

About the Author

Epic Research
Epic Research
Epic Research - Investment Adviser is a leading financial services provider with presence in Indian and other global capital markets. Call on - 0731-664-2300